KYKOF News and Press, Kyowa Hakko Kogyo From 07/25/22

Kirin announced a credible medium-term plan, highlighting opportunities for growth and improving profitability. There are limits to what Kirin can achieve in the face of current inflationary cost pressures, and the domestic price hike announcement highlights its significance. Cons...

Kyowa Kirin ( OTCPK:KYKOF ) expands the license agreement with Synaffix, by adding one new ADC to a total of three ADC programs. Kyowa Kirin also exercises exclusive target option for development and commercialization against an undisclosed ADC target. ...

The European Union drug regulator's human medicines committee has recommended extending the indication of Koywa Kirin's (OTCPK:KYKOF) Crysvita medicine, according to the highlights of their latest meeting. Crysvita is manufactured by the Japanese pharmaceutical company and distributed by U.S....

Japan's Kyowa Kirin (OTCPK:KYKOF) is thinking of selling certain international assets which could bring in $1B, Bloomberg News reported citing people with knowledge of the matter. The company intends to explore the sale of some assets of its Kyowa Kirin International unit and has hired a...

The shares of MEI Pharma (NASDAQ:MEIP) are trading lower in the premarket Monday after the clinical-stage biotech disclosed that the company had made errors in the revenue recognition for its collaboration with Japanese drugmaker, Kyowa Kirin Co., Ltd (OTCPK:KYKOF). As a result, revenue was o...

Clinical-stage biotech, MEI Pharma (NASDAQ:MEIP -59.2%) has recorded the biggest intraday loss in over seven years as Wall Street reacts to the regulatory setback for the company’s cancer medication, zandelisib developed in partnership with Kyowa Kirin (OTCPK:KYKOF). With FDA requiring...

Kyowa Kirin Co., Ltd. press release (OTCPK:KYKOF): FY GAAP EPS of ¥97.39. Revenue of ¥352.25B (+10.6% Y/Y). For further details see: Kyowa Kirin Co., Ltd. GAAP EPS of ¥97.39, revenue of ¥352.25B

MEI Pharma (NASDAQ:MEIP) and Kyowa Kirin (OTCPK:KYKOF) gains 10.2% premarket after announcing that the Phase 2 TIDAL study evaluating zandelisib as a single agent for follicular lymphoma (FL) patients who received at least two prior systemic therapies demonstrated a 70.3% objective ...

The following slide deck was published by Kyowa Kirin Co., Ltd. in conjunction with this event. For further details see: Kyowa Kirin (KYKOF) Investor Presentation - Slideshow

Kyowa Kirin Co., Ltd. (OTCPK:KYKOF): Q2 GAAP EPS ¥46.65. Revenue of ¥165.02B (+4.6 Y/Y). Press Release For further details see: Kyowa Kirin reports Q2 results